The 2013 Import and Export Market for Vaccines, Antisera, and Other Blood Fractions in Turkey

On the demand side, exporters and strategic planners focusing on vaccines, antisera, and other blood fractions in Turkey face a number of questions. Which countries are supplying vaccines, antisera, and other blood fractions to Turkey? How important is Turkey compared to others in terms of the entire global and regional market? How much do the imports of vaccines, antisera, and other blood fractions vary from one country of origin to another in Turkey? On the supply side, Turkey also exports vaccines, antisera, and other blood fractions. Which countries receive the most exports from Turkey? How are these exports concentrated across buyers? What is the value of these exports and which countries are the largest buyers? This report was created for strategic planners, international marketing executives and import/export managers who are concerned with the market for vaccines, antisera, and other blood fractions in Turkey. With the globalization of this market, managers can no longer be contented with a local view. Nor can managers be contented with out-of-date statistics which appear several years after the fact. I have developed a methodology, based on macroeconomic and trade models, to estimate the market for vaccines, antisera, and other blood fractions for those countries serving Turkey via exports, or supplying from Turkey via imports. It does so for the current year based on a variety of key historical indicators and econometric models. In what follows, Chapter 2 begins by summarizing where Turkey fits into the world market for imported and exported vaccines, antisera, and other blood fractions. The total level of imports and exports on a worldwide basis, and those for Turkey in particular, is estimated using a model which aggregates across over 150 key country markets and projects these to the current year. From there, each country represents a percent of the world market. This market is served from a number of